Table 3.
Pharmacokinetic parameters of arctigenin after intravenous (i.v) and sublingual (s.l) AG administrations in beagle dogs (n = 6 per treatment group, results were presented as Mean ± SD).
| Parameters | Units | s.l (dose) |
i.v (dose) |
||
|---|---|---|---|---|---|
| 2.687 μmol/dog | 5.374 μmol/dog | 10.748 μmol/dog | 5.374 μmol/dog | ||
| C5 min | μmol/L | / | / | / | 0.53 ± 0.085 |
| Cmax | μmol/L | 0.04 ± 0.007 | 0.07 ± 0.24 | 0.1 ± 0.018 | / |
| Tmax | Min | 60 ± 16.44 | 112 ± 53.64 | 130.2 ± 70.20 | / |
| AUC0-t | Min μmol/L | 6.48 ± 1.13 | 11.93 ± 2.27 | 23.22 ± 3.10 | 16.44 ± 1.51 |
| AUC0-∞ | Min μmol/L | 6.56 ± 1.16 | 12.01 ± 2.26 | 23.22 ± 3.06 | 16.61 ± 1.50 |
| MRT0-∞ | Min | 162 ± 31.5 | 167.4 ± 21.36 | 195.6 ± 36.42 | 72 ± 11.94 |
| MRT0-t | Min | 168 ± 34.8 | 171 ± 23.16 | 198.6 ± 35.34 | 75 ± 12.42 |
| Vd | L/kg | 36.3 ± 8.22 | 46.3 ± 14.6 | 58.5 ± 29.3 | 36.1 ± 8.45 |
| CL | L/min/kg | 0.42 ± 0.09 | 0.46 ± 0.01 | 0.47 ± 0.06 | 0.33 ± 0.028 |
| t1/2 | Min | 61.8 ± 19.26 | 70.8 ± 24.36 | 84 ± 34.98 | 96 ± 24.84 |
| F | 72.5% | ||||